Not as much as you may think. An associate of mine has reviewed multiple wholesale and retail Nuedexta price quotes and has estimated that revenues to Avanir per patient (after an assumed 8% royalty is paid to CNS) would be approximately $4,000/year. That means it would take just 88,000 patients, or less than 6% of the total assumed 1.5M moderate-to-severe US PBA population by the end of 2015. This is an extremely rough and rudimentary calculation, but it is only meant to show how little market penetration is necessary to support one analyst's conservative price target.